Randomized Control Study in REsuscitation of SEpsis Trial
Launched by FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA · Jun 16, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the REsuscitation of SEpsis Trial (RESET), is studying the best type of fluid to give children with sepsis—a serious infection that can affect how well their organs work. The trial compares three fluids used to help children recover: normal saline (a saltwater solution), Ringer’s lactate (a fluid with salts and minerals), and Octaplas LG, a specially processed plasma product that contains important proteins and is carefully sterilized to reduce infection risk. Researchers want to see if Octaplas LG works better or is as safe as the other fluids in helping children recover from sepsis.
Children between 1 month and 18 years old who are in the pediatric intensive care unit with sepsis and need fluids to support their heart and blood flow may be eligible. If your child joins the study, they will be randomly assigned to receive one of the three fluids alongside standard sepsis treatments like antibiotics and monitoring. They will stay in the study for up to 28 days or until they no longer need intensive care. Participation is voluntary, and choosing not to join will not affect your child’s medical care. This study aims to include about 150 children and could help doctors find better ways to treat sepsis in young patients.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Age: ≥1 month (corrected gestational age) to 18 years.
- * Diagnosis of sepsis with at least one of the following conditions:
- • Signs of poor perfusion: prolonged capillary refill ≥2 sec, weak peripheral pulses, unexplained metabolic acidosis (base deficit \> (-)5.0 mEq/L), altered. mental status, lactate ≥2 mmol/L (sample drawn without tourniquet use. (Appendix 2). OR
- • Systolic blood pressure (SBP) below the 5th percentile for age.
- • Signed informed consent from the patient's legal guardian.
- Exclusion Criteria:
- • Receipt of ≥2 boluses of NS 0.9% or balanced solution in the last 24 hours for the current sepsis episode (bolus defined as ≥10 mL/kg (max. 500 mL) of NS/RL given in \<30 min).
- • Known allergic reaction to plasma-derived products.
- • Known IgA deficiency.
- • Suspected or confirmed congestive heart failure.
- • Nephrotic syndrome.
- • Known chronic kidney disease with fluid overload or congestive heart failure.
- • Diagnosed hemorrhagic dengue fever confirmed by antigen or serology (NS1 or IgM positive).
About Fundación Cardioinfantil Instituto De Cardiología
Fundación Cardioinfantil Instituto de Cardiología is a prestigious healthcare institution dedicated to advancing cardiovascular health through innovative research and clinical trials. With a strong emphasis on improving patient outcomes, the foundation integrates cutting-edge medical practices with compassionate care, focusing on the diagnosis, treatment, and prevention of heart-related conditions. Committed to excellence in cardiology, the organization collaborates with leading experts and institutions to conduct rigorous research that informs clinical practices and enhances the understanding of cardiovascular diseases. Through its clinical trials, Fundación Cardioinfantil aims to contribute significantly to the field of cardiology, fostering advancements that benefit patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bogota, , Colombia
Patients applied
Trial Officials
Philp Spinella Dr, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported